Quantcast Arena Pharmaceutical Stock Quote | Stock Price for ARNA | Financial News | myMotherLode.com

Financial News

Motherlode Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Arena Pharmaceutical (NQ: ARNA)
39.99 USD  -0.54 (-1.32%)
Official Closing Price  /  Updated: 4:43 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 293,200
Open 40.50
Bid (Size) 36.50 (2)
Ask (Size) 44.05 (5)
Prev. Close 40.53
Today's Range 39.52 - 41.26
52wk Range 24.33 - 50.05
Shares Outstanding 49,234,094
Dividend Yield N/A
Performance
YTD
+10.45%
+10.45%
1 Month
-7.16%
-7.16%
3 Month
-8.65%
-8.65%
6 Month
+2.18%
+2.18%
1 Year
+46.61%
+46.61%
Top News
More News
Factors of Influence in 2018, Key Indicators and Opportunity within Meritor, Fred's, Arena Pharmaceuticals, AMERISAFE, Accelerate Diagnostics, and NextEra Energy — New Research Emphasizes Economic Gro
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Meritor, Inc.... Read More
from GlobeNewswire News Releases
Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor... Read More
from PR Newswire
More News
Read More
Stock Upgrades: Arena Pharmaceuticals Shows Rising Relative Strength
from Investor's Business Daily
Report Projects Annual Retail Sales of Cannabis in the U.S. to Exceed USD 20 Billion by 2022
from PR Newswire
Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
from PR Newswire
Biotech Rises On Crohn's Disease Study For Cannabinoid Drug
from Investor's Business Daily
Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
from PR Newswire
Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
from PR Newswire
Arena Pharmaceuticals to Present at Upcoming Investor Conferences
from PR Newswire
Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
from PR Newswire
Arena Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Follow myMotherLode.com at these social networks Make Us Your Homepage Today Follow us on Facebook Follow us on Twitter Follow us on Youtube Follow us on LinkedIn Follow our RSS Feed
Yellow Pages

Popular Searches

Local Radio Stations
© Copyright 2000-2017 Clarke Broadcasting Corporation. All rights reserved.